Tuesday, September 5, 2017

=Rexahn Pharmaceuticals (RNN)


  • Rexahn Pharmaceuticals (RNN) will present updated preliminary data from the Phase IIa study of RX-3117 in advanced and metastatic bladder cancer and also the final data on the Supinoxin Phase I clinical study at ESMO

Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)